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Abstract 
 
Deubiquitylating enzymes (DUBs) are proteases that reverse protein ubiquitylation and 
therefore modulate the outcome of this post-translational modification. DUBs regulate a 
variety of intracellular processes, including protein turnover, signalling pathways and DNA 
damage response. They have also been linked to a number of human diseases, such as cancer, 
inflammatory and neurodegenerative disorders. Whilst we are beginning to better appreciate 
the role of DUBs in basic cell biology and their importance for human health, there are still 
many unknowns. Central amongst these is a conundrum of how a small number of 
approximately 100 DUBs encoded in the human genome is capable of regulating the 
thousands of ubiquitin modification sites detected at steady-state conditions in human cells. 
This Commentary addresses the biological mechanisms employed to modulate and expand 
the functions of DUBs, and sets directions for future research aimed at elucidating the details 
of these fascinating processes.  
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Introduction 
 
Post-translational attachment of ubiquitin, or ubiquitylation, controls most intracellular 
processes, including protein turnover, intracellular signalling, endocytosis and DNA damage 
response (Clague and Urbe, 2017; Heideker and Wertz, 2015; Kee and Huang, 2015). 
Ubiquitin is conjugated most often to lysine residues of target proteins in a reaction catalysed 
by an enzymatic cascade that involves the E1 activating, E2 conjugating and E3 ligating 
enzymes. Importantly, ubiquitin can also be ligated to any of the seven internal lysine 
residues or the N-terminal methionine of another ubiquitin forming chains whose linkage 
type defines the outcome of protein ubiquitylation. Ubiquitylation can be reversed by 
deubiquitylating enzymes (DUBs) that cleave ubiquitin off the substrate protein or within 
ubiquitins in a polyubiquitin chain (Fig. 1). The importance of the components of the 
ubiquitin conjugation and deconjugation systems is underscored by the fact that their 
deregulation has been linked to the pathogenesis of a number of human diseases, such as 
cancer, neurodegenerative, inflammatory and metabolic disorders (Heideker and Wertz, 
2015). 
Approximately 100 DUBs are encoded in the human genome (Nijman et al., 2005b). 
Depending on the organisation of the catalytic domain, DUBs can be classified into distinct 
families (Table 1), a vast majority of which are cysteine proteases. These include ubiquitin-
specific proteases (USPs), ubiquitin C-terminal hydrolases (UCHs), ovarian tumour proteases 
(OTUs), Machado-Joseph disease proteases (MJDs) and the recently discovered (Abdul 
Rehman et al., 2016) MIU-containing novel DUB family (MINDY) proteases. Additionally, 
there is also a metalloprotease family of DUBs, the JAB1/MPN/Mov34 (JAMM) domain 
proteases (Nijman et al., 2005b). Strikingly, although DUBs have been implicated in many 
cellular processes, in most cases their precise function is still either poorly characterised or 
completely unknown. Importantly, there are at least 600 E3 ubiquitin ligases, and at steady-
state conditions, approximately 20,000 ubiquitylation sites on thousands of intracellular 
proteins can be detected (Clague et al., 2015; Kim et al., 2011; Udeshi et al., 2013). How a 
relatively small number of DUBs manages to regulate such a vast number of modifications is 
one of the key unsolved questions in the field. In this Commentary, we will discuss the 
different layers of regulation of DUB activity that ensure that DUBs are activated, regulated 
and targeted to their appropriate substrates to achieve precise spatio-temporal control of 
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ubiquitin signals within a specific physiological pathway. We will discuss these concepts 
with an emphasis on how functional diversification of DUBs can be achieved.  
 
 
Regulation of DUB abundance 
Conceptually, the simplest mechanism for modulating the activity, and hence biological 
function, of a given protein is by regulating its intracellular concentration. This also applies to 
DUBs whose abundance can be controlled both via transcription or translation and 
degradation. For example, levels of several DUBs are regulated in a cell cycle-dependent 
manner and are directly related to their function. USP37 is one such DUB, and its 
transcription is controlled by the E2F transcription factors, resulting in high USP37 levels 
during G1/S phase transition (Huang et al., 2011). This in turn allows for the stabilisation of 
cyclin A and cell cycle progression into S phase. Interestingly, USP37 is degraded in mitosis 
by the anaphase promoting complex APCCDH1 complex (Huang et al., 2011). Similarly, levels 
of USP33 oscillate during the cell cycle, which has implications for USP33-mediated 
stabilisation of CP110, a centriolar protein that controls cell cycle-dependent centrosome 
duplication (Li et al., 2013). Transcription of A20 and cylindromatosis (CYLD), modulators 
of NFκB signalling, is also tightly regulated and induced in response to NFκB activation in a 
feedback loop to inhibit the pathway (Pahl, 1999; Sun, 2010). Moreover, several DUBs are 
ubiquitylated and some, such as USP4 (Zhang et al., 2012), can autodeubiquitylate and hence 
counteract their own ubiquitin-mediated degradation. Therefore, transcriptional and post-
translational mechanisms regulate the abundance of DUBs and thus their functions. This 
regulation can also be cell type-specific, enabling fine tuning of ubiquitin signalling.  
 
Interacting partners of DUBs 
Interacting partners are key regulators of the biological functions of DUBs that can affect 
their catalytic activity and facilitate substrate recognition. Indeed, in some cases, a DUB is 
essentially inactive unless it is incorporated into a protein complex. This is particularly 
evident in the case of large macromolecular assemblies that contain DUBs as functional 
subunits. For example, all three proteasome-associated DUBs, the metalloprotease Rpn11 and 
the two cysteine proteases USP14 and UCH37, are significantly activated upon incorporation 
into the 19S regulatory particle (Borodovsky et al., 2001; Qiu et al., 2006; Worden et al., 
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2014; Yao et al., 2006). Recruitment of these DUBs not only enhances their catalytic activity 
but also places them within the context of the proteasome where they can influence different 
stages of protein degradation. Hence, USP14 and UCH37 can potentially modulate the 
ubiquitylation status of proteins prior to their commitment for degradation, whilst Rpn11 acts 
at later stages (Worden et al., 2014). Interestingly, UCH37 is also part of another complex, 
the chromatin-remodelling INO80 complex, in which its activity is inhibited (Yao et al., 
2008). Elegant structural studies revealed that equivalent DEUBiquitylase ADaptor 
(DEUBAD) domains present in both Rpn13 and INO80G induce distinct structural 
rearrangements in UCH37 that result in its activation at the proteasome and inhibition at the 
INO80 complex, respectively (Sahtoe et al., 2015; VanderLinden et al., 2015). 
Akin to the recruitment of UCH37 into two distinct complexes, the proteasome and the 
INO80 complex, BRCC36 (a member of the JAMM DUB family) is incorporated into two 
alternative complexes, the nuclear Abraxas complex (ARISC) and cytosolic BRCC36 
isopeptidase complex (BRISC). Both ARISC and BRISC complexes share the core subunits, 
BRCC45 and MERIT40, but in addition they also contain complex-specific components: 
Abro1 (also known as KIAA0157) for the BRISC complex and Abraxas for the ARISC 
complex (Feng et al., 2010). On its own, BRCC36 is largely inactive, whereas, as part of the 
cytosolic BRISC complex, BRCC36 is activated by its subunit Abro1 (Feng et al., 2010; 
Zeqiraj et al., 2015). In contrast, activation of BRCC36 within the nuclear ARISC requires 
concerted action of its core components, as well as the Abraxas and RAP80 subunits (Feng et 
al., 2010).  Importantly, incorporation of BRCC36 into these two distinct complexes defines 
its intracellular localisation and biological function. As a result, ARISC-incorporated 
BRCC36 functions in DNA damage repair (Shao et al., 2009), whereas BRISC-recruited 
BRCC36 stabilises type I interferon receptor by preventing its endocytosis and lysosomal 
degradation (Zheng et al., 2013), and affects mitotic spindle assembly by deubiquitylating 
nuclear mitotic apparatus protein 1 (NuMA) (Yan et al., 2015).  
The Spt-Ada-Gcn5-Acetyl transferase (SAGA) complex is another multisubunit assembly 
that ensures the correct localisation and substrate recognition by a DUB, in this case USP22. 
The SAGA complex acts as a transcriptional coactivator by catalysing acetylation and 
deubiquitylation of histone H2B. This latter activity is mediated by the SAGA 
deubiquitylating module (mDUB), which in mammals, is composed of the subunits USP22, 
ATXN7L3, ENY2 and ATXN7 (yeast Ubp8, Sgf11, Sus1 and Sgf73, respectively) (Koutelou 
et al., 2010). Importantly, whilst USP22 (Ubp8) is the only DUB, the remaining three 
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components within the mDUB are also critically required for the deubiquitylating activity 
(Lee et al., 2005). The crystal structures of yeast mDUB provided a rationale for this by 
revealing that all subunits form extensive contacts with each other in a manner that could 
stabilise and activate Ubp8 (Kohler et al., 2010; Samara et al., 2010). Interestingly, 
ATXN7L3 and ENY2 of mammalian mDUB also bind to and activate two additional DUBs, 
USP27X and USP51, although not as part of the SAGA complex (Atanassov et al., 2016). 
This suggests that these two non-catalytic subunits of mDUB could act as master regulators 
of histone H2B deubiquitylation by multiple DUBs.  
Additional examples of the widespread modulation of DUB functions by interacting partners 
include the regulation of the catalytic activities of USP1, USP12 and USP46 by USP1-
associated factor 1(UAF1) and WD repeat-containing proteins (Cohn et al., 2009; Kee et al., 
2010). Similarly, interaction of USP10 with the Ras-GTPase activating protein G3BP affects 
the catalytic activity of USP10 and the G3BP-USP10 complex regulates the formation of 
stress granules in response to phosphorylation of eukaryotic initiation factor 2α or inhibition 
of eukaryotic initiation factor 4A (Kedersha et al., 2016; Soncini et al., 2001). Furthermore, 
spermatogenesis-associated protein 2 (SPATA2) acts as a scaffold protein that links CYLD to 
HOIL-1L-interacting protein (HOIP), an E3 ligase component of the linear ubiquitin chain 
assembly complex (LUBAC), and so controls the outcome of tumour necrosis factor receptor 
1 (TNFR1)-mediated signalling (Elliott et al., 2016; Kupka et al., 2016; Schlicher et al., 2016; 
Wagner et al., 2016). In a similar manner, interactions of USP8 and associated-molecule-
with-the-SH3-domain-of-signal-transducing-adapter-molecule-1 (AMSH) with signal-
transducing-adapter-molecule-1 (STAM) and endosomal-sorting-complex-required-for-
transport-III (ESCRT-III) components ensure the endosomal localisation of these DUBs and 
thereby support their function in endocytosis (Clague and Urbe, 2017; Millard and Wood, 
2006). The examples of DUB interactions listed above highlight the importance of binding 
partners in regulating DUB biology and show how the same DUB can perform different 
functions depending on its interacting proteins. We anticipate that such regulation is widely 
prevalent, and it will be important to study DUBs within the context of such complexes and 
their constituent proteins. 
 
Regulating DUB function by antagonising ubiquitylation 
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In addition to interacting with scaffold proteins, DUBs are also often found in complexes 
with other components of the ubiquitin system such as E3 ubiquitin ligases (Sowa et al., 
2009). The presence of such complexes can reflect several scenarios. For example, DUBs can 
reverse autoubiquitylation of E3 ligases and prevent their degradation. Moreover, DUBs are 
also targets of E3 ligase-mediated ubiquitylation (Huang et al., 2011; Mashtalir et al., 2014; 
Scaglione et al., 2011; Seki et al., 2013; Todi et al., 2009; Wijnhoven et al., 2015). 
Importantly, in recent years it has become clear that DUBs and E3 ligases can co-operate to 
dictate the outcome of protein ubiquitylation. In such a scenario, a DUB limits or modulates 
the linkage type of polyubiquitin generated by an E3 ubiquitin ligase (Fig. 2). For example, 
the monoubiquitylated form of the E3 ubiquitin ligase carboxy-terminus-of-Hsp70-
interacting-protein (CHIP) recruits the DUB ataxin-3, which limits the elongation of 
polyubiquitin on CHIP substrates (Scaglione et al., 2011). Importantly, such an editing of 
polyubiquitylation appears to be important for the degradation of CHIP substrates, as 
expression of catalytically inactive ataxin-3 or mutation of the ubiquitylation site on CHIP 
that serves to recruit ataxin-3 both perturb the degradation of CHIP substrates (Scaglione et 
al., 2011). Ataxin-3 also deubiquitylates CHIP upon completion of substrate ubiquitylation, 
therefore contributing to the termination of the ubiquitylation cycle.  
In a similar manner, the E3 ligase LUBAC interacts with two DUBs capable of cleaving 
linear polyubiquitin, OTULIN and CYLD (Takiuchi et al., 2014). This interaction occurs 
through the N-terminal PUB domain of the HOIP subunit of LUBAC and is critical in 
controlling the in vitro generation and in vivo levels of linear ubiquitin chains (Elliott et al., 
2014; Schaeffer et al., 2014). Importantly, interaction of HOIP with these two DUBs plays a 
key role in inhibiting the extent of NFκB activation following TNFα treatment. By being 
associated with E3 ubiquitin ligases, DUBs can negatively regulate E3 ligase activity, and 
thus activation of the E3 would require dissociation or inhibition of the DUB (Fig. 2). In an 
alternative model, DUBs cleave certain linkage types to edit the ubiquitin signal that has been 
assembled by the E3 ligase, which results in a different linkage type or monoubiquitylation of 
the substrate (Fig. 2). In both scenarios, co-operation between a DUB and an E3 ubiquitin 
ligase can orchestrate the strength and functional outcome of ubiquitin signal.  
Otubain-1 (OTUB1) employs yet another mechanism to antagonise protein ubiquitylation. 
Although OTUB1 is a DUB with an enzymatic activity that is specific for Lys48-linked 
chains, it can also suppress protein ubiquitylation in a manner that is independent of its 
catalytic activity by binding to ubiquitin-charged E2 enzymes such as UBE2N (Nakada et al., 
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2010). As revealed by structural studies, the binding of OTUB1 to UBE2N inhibits 
ubiquitylation by blocking the formation of an isopeptide bond between donor and acceptor 
ubiquitin, hindering access to the E3 enzyme and preventing interaction between donor 
ubiquitin and the E2 enzyme (Juang et al., 2012; Wiener et al., 2012). This non-catalytic 
function of OTUB1 plays an important role in suppressing Lys63-linked ubiquitylation of 
chromatin at DNA double-strand breaks in response to, for example, ionising radiation 
(Nakada et al., 2010). Interestingly, OTUB1 also interacts with other E2 enzymes that can 
assemble ubiquitin chains distinct from Lys63-linked ones suggesting that OTUB1-mediated 
inhibition of ubiquitylation might have a wide-spread function (Nakada et al., 2010). 
Expanding on the theme of catalytic-independent modulation of protein ubiquitylation, there 
are many DUBs that lack key catalytic residues and are predicted to be inactive. We speculate 
that due to the presence of an otherwise intact DUB domain, these pseudoDUBs might 
compete with catalytically active DUBs for substrate or could function as ubiquitin-binding 
domains. Analogous to UBE2N-UBE2V1, the E2-pseudoE2 pair that work together to 
assemble Lys63-linked polyubiquitin, one could envisage pseudoDUBs enhancing or 
inhibiting the activity of DUBs.  
In summary, interactions between DUBs and their partners regulate many aspects of DUB 
biology, such as their catalytic activities and substrate recognition. Interactions with other 
proteins also constitute one of several mechanisms that define the intracellular localisation of 
DUBs – another aspect instrumental for DUBs to fulfil their biological roles. Given the 
profound effect that interacting partners exert on DUB functions it will be crucial to 
understand their identities under various conditions and in different types of cells or tissues.  
 
Localisation-dependent DUB functions 
The subcellular localisation of DUBs (Fig. 3) has several important consequences for their 
functions. It defines, for example, access of a DUB to a specific substrate and, therefore, roles 
within a particular physiological pathway. This is especially evident in case of the 
transmembrane DUBs USP19 and USP30 whose intracellular localisation is highly restricted. 
Endoplasmic reticulum (ER) localisation of USP19 is crucial for its function in the ER-
associated degradation pathway (ERAD) ((Hassink et al., 2009) but see also (Lee et al., 2014) 
where USP19 involvement in ERAD has been questioned), secretion of misfolded proteins 
upon proteasome dysfunction (Lee et al., 2016) and ER exit of membrane proteins that fold 
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inefficiently (Perrody et al., 2016). Similarly, USP30, which is localised to the mitochondrial 
outer membrane, regulates mitochondrial morphology (Nakamura and Hirose, 2008) and has 
been implicated in Parkin-mediated mitophagy (Bingol et al., 2014; Liang et al., 2015). In the 
same manner, nucleolar localisation of USP36 allows it to specifically interact with and 
deubiquitylate a nucleolar pool of c-Myc (Sun et al., 2015), whereas endosome-localised 
AMSH and USP8 regulate the lysosomal degradation and recycling of receptor tyrosine 
kinases such as epidermal growth factor receptor (EGFR) (Clague and Urbe, 2017; Millard 
and Wood, 2006).  
In principle, the repertoire of DUB substrates, and hence the biological functions of DUBs, 
can be expanded by ensuring that a single DUB is present at alternative locations within the 
cell. Indeed, a number of DUBs were shown to simultaneously localise to distinct 
intracellular structures. A computational analysis identified potential nuclear export signals 
(NESs) in many DUBs that would allow for their shuttling between the nucleus and cytosol  
(Garcia-Santisteban et al., 2012), a prediction that has been experimentally validated for 
USP21(Garcia-Santisteban et al., 2012). Indeed, the presence of such a NES might account 
for the dual role of USP21 in regulating transcription via histone H2A deubiquitylation in the 
nucleus (Nakagawa et al., 2008) and in primary cilia formation and cilia-related Hedgehog 
signalling when it is localised to the centrosome (Heride et al., 2016; Urbe et al., 2012). In a 
similar manner, USP12 deubiquitylates histones H2A and H2B (Joo et al., 2011), but also 
translocates from the nucleus following T cell receptor (TCR) stimulation to deubiquitylate 
and stabilise the TCR adaptor proteins linker-for-activation-of-T-cells-family-member-1 
(LAT) and T-cell-receptor-associated-transmembrane-adapter-1 (Trat1) at the cell surface 
(Jahan et al., 2016). 
Alternative localisation is also intrinsically linked to the function of CYLD, which is 
recruited to the necrosome complex where it deubiquitylates receptor-interacting-
serine/threonine-protein-kinase-1 (RIP1) and contributes to necroptosis progression (Liu et 
al., 2016). At the same time, CYLD can also interact with several centrosomal proteins, such 
as CEP192 (Gomez-Ferreria et al., 2012), CAP350 (Eguether et al., 2014) and CEP70 (Yang 
et al., 2014b), and this centrosomal pool of CYLD has been shown to regulate primary cilia 
formation and mitotic spindle assembly and/or orientation (Eguether et al., 2014; Gomez-
Ferreria et al., 2012; Yang et al., 2014a; Yang et al., 2014b). Similarly, USP15 
deubiquitylates histone H2B in the nucleus (Long et al., 2014), prevents degradation of the 
transcriptional repressor RE1-silencing-transcription-factor (REST) at the ribosome 
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(Faronato et al., 2013) as well as opposes RNF26-mediated ubiquitylation of p62 at the ER, 
thus regulating the mobility of endosomes (Jongsma et al., 2016). These examples highlight 
how DUBs can exert different functions just by being at different places, a theme that is 
being increasingly explored. 
 
Post-translational modifications 
The function of many, if not most, proteins is regulated by their post-translational 
modifications (PTMs). This is also true for DUBs which are targets of many PTMs such as 
phosphorylation, ubiquitylation, SUMOylation, lipidation and oxidation, all of which can 
affect the biology of DUBs and are discussed here. 
Phosphorylation 
Phosphorylation is a key post-translational modification that affects the function of a number 
of DUBs, highlighting the crosstalk between enzymes that regulate different PTMs, in this 
case phosphorylation and ubiquitylation. Phosphorylation has been observed to either 
activate, inhibit or modulate the catalytic activity of DUBs (Fig. 4A). Deubiquitinating 
enzyme A (DUBA, also known as OTUD5) is a negative regulator of immune responses 
(Kayagaki et al., 2007). For a long time, it has been puzzling as to why bacterially expressed 
recombinant DUBA was not an active enzyme (Huang et al., 2012). An answer to this came 
from the demonstratation that casein kinase 2 (CK2)-mediated phosphorylation at Ser177 
within the catalytic domain activates DUBA (Huang et al., 2012), representing the first 
example for how phosphorylation could activate a DUB. 
USP14 can also be activated by phosphorylation in a manner that is distinct from its 
proteasome-dependent activation (Xu et al., 2015) (see also above). When phosphorylated by 
RAC- serine/threonine-protein-kinase (AKT) at Ser432, USP14 is activated independently of 
the proteasome and is then able to cleave polyubiquitin that is linked via Lys48 to stabilise 
proteasomal substrates or Lys63 to control non-degradative outcomes of ubiquitylation. For 
example, by removing Lys63-linked polyubiquitin from Beclin-1, phosphorylated USP14 
decreases the association of Beclin-1 with Atg14L and UV-radiation-resistance-associated-
gene-protein (UVRAG), and so downregulates autophagy (Xu et al., 2016).  
USP10, USP37 and USP9X are further examples of DUBs that are activated by 
phosphorylation. Phosphorylation at Ser76 by AMP-activated-protein-kinase (AMPK) 
activates USP10, which can then remove Lys63-linked polyubiquitin from the activation loop 
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of AMPK (Deng et al., 2016). This in turn enables liver-kinase-B1 (LKB1)-mediated 
phosphorylation of AMPK at Thr172, leading to further AMPK activation. Hence, AMPK-
dependent phosphorylation of USP10 establishes a positive feedback loop for enhancing 
AMPK activity during conditions of energy stress. Consistent with such a scenario USP10 
depletion in mouse liver leads to metabolic defects such as an increase in triglyceride and 
cholesterol content (Deng et al., 2016). By contrast, USP37 is activated in a cell cycle-
specific manner by CDK2-mediated phosphorylation at Ser628 (Huang et al., 2011). This 
regulated activation is fundamental for its ability to antagonise APCCDH1-mediated 
degradation of cyclin A, thus controlling cell cycle progression into S phase (Huang et al., 
2011). In case of USP9X its phosphorylation at Ser1600 occurs in response to TCR activation 
and enhances its catalytic activity (Naik and Dixit, 2016). This in turn facilitates USP9X 
interactions with components of the TCR signalling cascade and ultimately leads to 
deubiquitylation of ZAP70 preventing its sequestration in early endosomes (Naik and Dixit, 
2016).  
Phosphorylation can also inhibit the catalytic activity of DUBs as shown for CYLD upon its  
phosphorylation at Ser418 by inhibitor-of-nuclear-factor-kappa-B-kinase-subunit-epsilon 
(IKKε) (Hutti et al., 2009). In this case, phosphorylated CYLD is less efficient at removing 
polyubiquitin from its substrates, for example TRAF2, following TNFα stimulation. 
Importantly, phosphorylation-deficient CYLD significantly limits the size of tumours 
resulting from the introduction of IKKε-transformed cells into immunodeficient mice (Hutti 
et al., 2009). This in turn suggests that CYLD phosphorylation is required to induce 
oncogenic transformation mediated by IKKε (Hutti et al., 2009). 
An interesting example of phosphorylation-mediated regulation of DUB function is 
illustrated by A20, an OTU-domain containing DUB. A20 is unique amongst DUBs as it 
combines DUB and E3 ubiquitin ligase activities within a single polypeptide chain (Wertz et 
al., 2004). Hence, A20 removes Lys63-linked polyubiquitin from RIP1 and, by assembling 
Lys48-linked chains, mediates its proteasomal degradation. This in turn shifts the outcome of 
RIP1 ubiquitylation from a prosurvival to a proapoptotic signal (Wertz et al., 2004). This 
activity is controlled by phosphorylation of A20 on Ser381 within the Zinc Finger region by 
IKKβ, which enhances the hydrolysis of Lys63-linked polyubiquitin and activates the E3 
ubiquitin ligase activity (Wertz et al., 2015). 
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In addition to directly affecting the catalytic activity of DUBs, phosphorylation can also 
indirectly regulate DUB function, for example, by changing their subcellular localisation. For 
instance, phosphorylation of USP4 at Ser445 that is mediated by AKT triggers USP4 
translocation from the nucleus to the cytosol and intracellular membranes (Zhang et al., 
2012). This enables USP4-catalysed deubiquitylation of transforming-growth-factor-beta 
(TGFβ) type I receptor, which in turn extends its half-life at the plasma membrane and 
induces TGFβ signalling. This function of USP4 has been shown to stimulate TGFβ-induced 
breast cancer cell invasion and metastasis (Zhang et al., 2012). Similarly, when 
phosphorylated at Ser16 by CK2, OTUB1 accumulates in the nucleus, and its 
phosphorylation status impacts on the formation of 53BP1-positive foci following ionising 
radiation-induced DNA damage (Herhaus et al., 2015). Phosphorylation is therefore 
emerging as an important regulator of DUB function, as it not only regulates the activity of 
DUBs, but also their interactions and subcellular localisation.  
 
Ubiquitylation and SUMOylation 
Modification of DUBs with ubiquitin and ubiquitin-like molecules constitutes another mode 
of regulating their activities (Fig. 4A). For example, monoubiquitylation of ataxin-3, a DUB 
implicated in Spinocerebellar Ataxia Type 3, enhances its catalytic activity (Todi et al., 
2009). Ubiquitylation of JosD1, another MJD family DUB, in addition to activating it also 
leads to its relocalisation from the cytoskeletal to the membrane fraction as assessed by 
subcellular fractionation (Seki et al., 2013). In an analogous manner, UBE2O-mediated 
ubiquitylation of lysine residues located in the proximity of the nuclear localisation sequence 
of BRCA1-associated protein 1 (BAP1) leads to an accumulation of ubiquitylated BAP1 in 
the cytosol (Mashtalir et al., 2014). Interestingly, BAP1 can also mediate its own 
deubiquitylation, and BAP1 mutations that result in increased levels of its ubiquitylated form 
have been linked to cancer (Mashtalir et al., 2014). A similar autodeubiquitylation event has 
been described for USP4, a DUB implicated in the DNA damage repair pathway (Wijnhoven 
et al., 2015). Interestingly, USP4 is modified by unconventional cysteine ubiquitylation, 
which blocks its interaction with the key DNA damage repair proteins CtBP-interacting 
protein (CtIP) and RAD50 (Wijnhoven et al., 2015). The same report also suggests that a 
related DUB, USP15, is similarly ubiquitylated on a cysteine residue and this modification 
affects its interaction with the TGFβ signalling pathway components SMAD2 and SMAD3 
	   13 
(Wijnhoven et al., 2015). Furthermore, USP15 can also promote its own autodeubiquitylation 
(Wijnhoven et al., 2015).  
SUMOylation is closely related to ubiquitylation and has also been shown to regulate the 
activities of DUBs. USP25 is modified by SUMO preferentially at lysines 99 and 141, which 
are located within the first ubiquitin interacting motif (UIM) and adjacent to the second UIM, 
respectively (Meulmeester et al., 2008). This modification inhibits polyubiquitin hydrolysis 
by USP25, most likely by blocking the binding of ubiquitin to its UIM. Similarly, 
SUMOylation of CYLD inhibits CYLD-mediated deubiquitylation of components of the 
NFκB signalling pathway (Kobayashi et al., 2015). 
 
Other modifications 
Several other PTMs have been implicated in regulating the biology of DUBs. For example, 
farnesylation of UCH-L1 promotes its association with intracellular membranes and 
stimulates the accumulation of α-synuclein, which has been linked to Parkinson’s disease, in 
neuroblastoma cells (Liu et al., 2009). The DUBs USP32, MINDY-1 and MINDY-2 are also 
predicted to be modified with lipids, which might account for the association of USP32 with 
intracellular membranes (Abdul Rehman et al., 2016; Akhavantabasi et al., 2010). Finally, 
reversible oxidation of the catalytic cysteine of DUBs that inhibits their activity has also been 
reported (Cotto-Rios et al., 2012; Kulathu et al., 2013; Lee et al., 2013); this could provide an 
attractive model for how ubiquitin signals can be amplified when DUB activity is reversibly 
inhibited in a spatio-temporal manner in response to production of reactive oxygen species.  
 
Expanding DUB functionality with DUB isoforms 
A median of five isoform transcripts has been reported for human genes, although this 
number can vary significantly (Floor and Doudna, 2016). Such alternative splicing and/or the 
use of alternative transcription initiation sites constitute an attractive mode of how the 
biological functions of DUBs can be further expanded. This is particularly important in light 
of a recent study suggesting that alternative protein isoforms behave more like unrelated 
proteins, rather than slight variations of the same polypeptide (Yang et al., 2016). 
Importantly, depending on the tissue analysed, alternative isoforms might be actually more 
abundant than the so-called canonical ones (Yang et al., 2016).  
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The following examples highlight why it is important to consider isoforms when studying 
DUBs. As with many other proteins, the functional expansion of DUBs by their various 
isoforms remains largely unexplored. One notable exception is USP19, for which two 
isoforms have been described that differ in their C-terminal region. As a consequence, one 
isoform contains a membrane-spanning region and is embedded within the ER membrane, 
whereas the second isoform is cytoplasmic. Importantly, the cytosolic isoform cannot 
substitute for the ER-localised one in processes, such as ER-associated degradation or 
secretion of misfolded proteins (Hassink et al., 2009; Lee et al., 2016). A similar isoform-
specific localisation was observed for USP33, for which at least three different isoforms have 
been reported (Thorne et al., 2011). Although all of these associate with the ER, isoform 3 
accumulates at the Golgi apparatus due to a deletion of eight amino acids that act as a “Golgi 
exclusion signal” (Thorne et al., 2011). Reminiscent of the isoform-specific localisation of 
USP33, USP35 has also been suggested to exist as two isoforms that localise either to the 
cytosol or mitochondria (Wang et al., 2015). The latter isoform contains a predicted 
mitochondria-targeting sequence and has been suggested to have a role in mitophagy (Wang 
et al., 2015). However, the existence of the transcript or protein that corresponds to the 
putative USP35 mitochondrial isoform has not been confirmed experimentally and its 
potential function thus remains speculative at this point. 
Finally, two isoforms of OTUB1 that differ in their N-terminal regions due to the use of 
alternative translation initiation sites have also been reported. Catalytically active OTUB1 is 
ubiquitously expressed, whereas the second catalytically-inactive isoform, called ARF-1, is 
predominantly produced in tissues of the immune system, such as tonsils and lymph nodes 
(Soares et al., 2004). Both isoforms interact with the E3 ubiquitin ligase gene-related-to-
anergy-in-lymphocytes-protein (GRAIL), but, surprisingly, OTUB1 destabilises GRAIL, 
whereas the catalytically inactive isoform ARF-1 increases GRAIL levels. This might be due 
to differential, isoform-specific, regulation of USP8 activity, another DUB proposed to 
directly deubiquitylate GRAIL. Consistent with their differing effects on GRAIL, the two 
OTUB1 isoforms have opposing roles in anergy and cytokine production following T cell 
activation (Soares et al., 2004). 
Interestingly, a recent high-throughput study indicates that mRNAs corresponding to multiple 
DUB isoforms associate with translating ribosomes in HEK293 cells, suggesting that they are 
indeed produced (Floor and Doudna, 2016). However, for most of these transcripts the 5’- or 
3’-coding sequences are not annotated, making it difficult to unambiguously determine the 
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amino acid sequence of these isoforms. Nonetheless, the generation of multiple isoforms by 
alternative splicing could be an important mechanism for not only expanding the repertoire of 
available DUBs, but also for ensuring the dynamic regulation of ubiquitylation in a cell-type- 
or tissue-specific and stimulus-dependent manner.  
 
Regulation of DUB function by proteolytic processing 
Alternative splicing often results in the generation of isoforms that correspond to N- or C-
terminal truncations of the “canonical” isoform. A similar effect could in principle be 
achieved post-translationally by proteolytic processing of DUBs, and indeed this mode of 
regulation has recently emerged as yet another mechanism of regulating DUB function (Fig. 
4B). For example, USP7 is cleaved by caspase-3 during dexamethasone-triggered apoptosis 
in foetal thymic organ culture (Vugmeyster et al., 2002). Such proteolysis of USP7 generates 
a truncated protein that is still active as evidenced by its reactivity with a DUB-selective 
probe that modifies the catalytic cysteine of an active DUB. The role of this cleavage is 
unknown, but it could potentially alter the interactions of USP7 with other proteins during 
apoptosis. The DUB USP8 also undergoes proteolytic processing and several mutations of 
USP8 that cluster in the vicinity of its binding site for the 14-3-3 proteins were identified in 
Cushing’s disease tumours (Ma et al., 2015; Reincke et al., 2015). These mutations disrupt 
the interaction of USP8 with 14-3-3 proteins, previously reported to inhibit USP8 catalytic 
activity (Mizuno et al., 2007), and make USP8 susceptible to the action of an unknown 
protease, which cleaves USP8 between Lys714 and Arg715 (Reincke et al., 2015). This, in 
turn, leads to release of a C-terminal USP8 fragment (tUSP8) that has increased catalytic 
activity (Reincke et al., 2015). The tUSP8 variant can still interact with EGFR and is very 
efficient at deubiquitylating EGFR. Disease mutants result in truncated USP8 that now 
promotes EGFR recycling to the plasma membrane, instead of downregulating the receptor. 
Interestingly, USP8 is also cleaved in a caspase-dependent manner in T cells following TCR 
activation (Dufner et al., 2015). 
Proteolytic processing of DUBs is also employed to block their biological activities. Caspase-
8-mediated cleavage of CYLD at Asp215 serves to inactivate CYLD and confers a 
prosurvival signal during necroptosis (O'Donnell et al., 2011). Interestingly, whilst the 
caspase-8-mediated cleavage occurs outside the catalytic domain of CYLD, the released C-
terminal fragment containing its USP domain is unstable and is degraded by the proteasome. 
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This CYLD proteolysis is important to inhibit necroptosis in macrophages stimulated with 
LPS (Legarda et al., 2016).  
A20 is another DUB that is inactivated by proteolytic cleavage (Coornaert et al., 2008). 
Processing of A20 by a paracaspase mucosa-associated-lymphoid-tissue-lymphoma-
translocation-protein-1 (MALT1) at Arg439 generates an intact OTU domain that is unstable 
(Coornaert et al., 2008). A20 cleavage occurs in response to TCR stimulation and impairs its 
role in inhibiting NF-κB activation (Coornaert et al., 2008).  
An interesting mechanism for inactivating a DUB by proteolytic cleavage was shown for 
USP1, a DUB that deubiquitylates monoubiquitylated PCNA in the translesion synthesis 
pathway, and monoubiquitylated Fanconi Anemia group I protein (FANCI) and Fanconi 
Anemia group D2 protein (FANCD2) of the Fanconi Anemia interstrand crosslink repair 
pathway (Nijman et al., 2005a; Sims et al., 2007; Smogorzewska et al., 2007). Upon 
ultraviolet irradiation, USP1 undergoes autocleavage, thus resulting in the accumulation of 
monoubiquitylated PCNA, an event important for DNA damage repair (Huang et al., 2006). 
Strikingly, this autocleavage event occurs immediately after a Gly-Gly repeat, a motif also 
found in linear ubiquitin fusions such as ubiquitin precursors (Baker and Board, 1991; Lund 
et al., 1985; Redman and Rechsteiner, 1989; Wiborg et al., 1985). Because numerous other 
DUBs also contain Gly-Gly motifs, autocleavage to modulate DUB activity could be more 
widespread than currently appreciated. Importantly, as is the case for the autocleaved USP1 
(Piatkov et al., 2012), proteolytically processed DUBs might expose destabilising residues at 
their newly generated N-terminus, which would lead to their degradation via the N-end rule 
pathway.  
 
Conclusions and perspectives 
DUBs are key regulators of a plethora of intracellular processes and as such have been 
implicated in the pathogenesis of a number of human disorders (Heideker and Wertz, 2015). 
Accordingly, DUBs have been a topic of intense research, and recent years have seen an 
explosion in the number of reports addressing their mechanisms of action and biological 
roles. However, we are still very far from having a complete picture of DUB biology. One of 
the main unanswered questions is how do the small number of approximately 100 enzymes 
modulate a multitude of ubiquitylation events that occur in eukaryotic cells? We postulate 
that an expansion of DUB function via the many mechanisms discussed here will be crucial 
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for the regulation of ubiquitylation. Clearly, further work is needed to fully understand the 
extent to which such functional expansion is employed. For example, analysis of transcription 
and translation of DUB isoforms in various organs and under a range of experimental 
conditions will be invaluable for our understanding of the total number of different DUB 
polypeptides that are produced and that could have distinct functional capabilities. Moreover, 
exploitation of techniques to identify transient and weak affinity protein-protein interactions 
will be instrumental in defining the atlas of DUB regulators and interactors. This will help to 
reveal the full set of biological pathways in which DUBs participate, their regulation within 
these pathways, and thus a full appreciation of DUB function in eukaryotic cell biology. We 
also anticipate that the outcome of DUB-focused research will contribute to deciphering the 
molecular basis of the pathogenesis of human disorders and thus lead to novel or improved 
therapeutic strategies. We hope that the paradigms presented in this Commentary of how 
diversification and regulation of DUB function is achieved will guide future research. 
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FIGURE LEGENDS 
Fig. 1. Overview of protein ubiquitylation.  
Ubiquitin is activated and transferred to a substrate protein in a cascade reaction catalysed by 
E1 activating, E2 conjugating and E3 ligating enzymes. This can lead to the formation of 
distinct types of modifications, all of which can potentially be reversed by deubiquitylating 
enzymes (DUBs). Numbers in brackets indicate the number of members for each family of 
enzymes.  
Fig. 2. Mechanisms of DUB-mediated modulation of protein ubiquitylation.  
(A) DUBs can cleave polyubiquitin either from the distal end (exoDUBs) or within the chain 
(endoDUBs). (B) DUBs act in concert with E3 ubiquitin ligases to modulate protein 
ubiquitylation. For example, partial deubiquitylation can leave a ubiquitin moiety attached to 
a substrate, which is then extended by an E3 ligase to form polyubiquitin of a distinct linkage 
type. (C-D) Alternatively, a DUB can remove a certain linkage type (shown in brown) or 
limit the length of the polyubiquitin chain ligated to a substrate. (E) DUBs can also 
constitutively counteract some E3 ligases whose activation requires DUB dissociation and/or 
inactivation. 
 
Fig. 3. Intracellular localisation of DUBs. 
DUBs have been reported to function in almost every intracellular compartment and have 
localisation-specific roles. Importantly, DUB functionality can be expanded by ensuring that 
a single DUB localises to distinct organelles as shown, for example, for USP15 and USP21. 
Such alternative localisation can be regulated by DUB interacting partners, post-translational 
modifications and alternative splicing, and the predominant steady-state localisation 
presumably depends on the experimental conditions used. The figure was generated based on 
both the localisation studies where available and the reported activities of DUBs at the 
indicated locations. 
 
 
 
Fig. 4. Additional modes of DUB regulation 
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(A) DUB function can be regulated by post-translational modifications (PTMs) that affect 
either DUB localisation or their catalytic activity. For example, phosphorylation of USP4 by 
AKT re-localises it from the nucleus to the cytosol. In contrast, CK2-mediated 
phosphorylation of OTUB1 triggers its translocation from the cytosol to the nucleus. DUB 
activities can also be modulated by PTMs such as phosphorylation, ubiquitylation and 
SUMOylation. The enzymes catalysing PTMs of selected DUBs are named above the arrows. 
(B) DUBs can also be proteolytically processed. This can lead to their degradation as 
exemplified by CYLD, which is cleaved by caspase-8 following the TNF receptor 1 (TNFR1) 
ligation (top). Alternatively, DUB proteolysis can result in a functional protein (illustrated 
below). The truncated form of USP8 (tUSP8) is present in some Cushing’s disease tumours 
and has increased catalytic activity. Like USP8, tUSP8 interacts with EGFR, and, owing to 
more efficient deubiquitylation, promotes EGFR recycling to the plasma membrane,  
resulting in sustained proliferative signalling. 
 
Table 1. DUBs are divided into several families.  
DUBs can be divided into distinct families that include ubiquitin-specific proteases (USPs), 
ubiquitin C-terminal hydrolases (UCHs), ovarian tumour proteases (OTUs), Machado-Joseph 
disease proteases (MJDs), MIU-containing novel DUB family (MINDY) proteases and the 
JAB1/MPN/Mov34 (JAMM) domain proteases. DUBs are cysteine proteases with the 
exception of the JAMM family that is composed of metalloproteases. Numbers of active and 
inactive members of each family of DUBs are given.  
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